| Literature DB >> 33515782 |
Marilyn Stern1, Heewon L Gray2, Kathy Ruble3, Sandra Soca Lozano4, Alexandra Albizu-Jacob5, Jeffrey M Williams5, Kamar Godder6, Bernard Fuemmeler7, Suzanne Mazzeo8.
Abstract
Approximately 40-50% of pediatric cancer survivors (PCS) are overweight or obese; increasing their risk for metabolic syndrome and other negative long-term physical health complications. Using our successful pilot trial testing the preliminary feasibility and efficacy of NOURISH for Healthy Transitions (NOURISH-T), we refined our intervention, now NOURISH-T+, and will implement these refinements in this larger, multi-site randomized control trial. Parents of PCS with overweight/obesity (BMI ≥ 85th%ile), age 5-12, ≥6 months off treatment are randomly assigned to the NOURISH-T+ intervention or Enhanced Usual Care (EUC) comparison. Parents in NOURISH-T+ will participate in a 6-session, manualized intervention, with an additional dietician session and 2 PCS sessions, as well as post-intervention booster sessions. EUC consists of a one-time informational session, nationally available brochures and follow-up check-ins. Both study conditions will be conducted remotely via a videoconferencing platform. Parents and PCS will be assessed on anthropometric measures, physical activity (PA) and dietary behaviors at baseline, 3-, 6-, and 12-months post-intervention. We will enroll a diverse group of 260 parents/PCS dyads from four pediatric oncology clinics with the aim of evaluating the efficacy of our intervention across diverse pediatric oncology clinics. Our main aim is to compare the impact of NOURISH-T+ with EUC on PCS BMI z-score. Secondary aims are to compare intervention impact on PCS PA and eating behaviors and parent BMI and behaviors as well as to explore potential moderators of the intervention. Our longer-term goal is to establish a framework for future translation and dissemination of NOURISH-T+.Entities:
Keywords: Intervention; Obesity; Pediatric cancer survivors; Randomized control trial
Mesh:
Year: 2021 PMID: 33515782 PMCID: PMC8009853 DOI: 10.1016/j.cct.2021.106296
Source DB: PubMed Journal: Contemp Clin Trials ISSN: 1551-7144 Impact factor: 2.226